OBJECTIVES: To confirm associations of apolipoprotein E (ApoE) ε4 carrier status, sex, and time-dependent cognitive status with mortality risk and to investigate these joint effects of these associations in a cohort of community-dwelling U.S. adults. DESIGN: Prospective cohort study. SETTING: The Baltimore Longitudinal Study of Aging (BLSA). PARTICIPANTS: Of 3,047 BLSA participants aged 17 to 98 at first visit (60.1% male), 1,704 with complete ApoE genotype data were included, of whom 1,461 aged 50 and older with one or more visits were eligible. MEASUREMENTS: Time to death from all, cardiovascular, and noncardiovascular causes. RESULTS: Probability of survival was lower for ApoE ε4 carriers, particularly those who were older. A Cox proportional hazards model for all-cause mortality yielded a hazard ratio (HR) for ApoE ε4 carrier versus noncarriers of 1.31 (95% confidence interval (CI) = 1.02-1.68). This association was also found for cardiovascular mortality. Time-dependent all-cause dementia (HR = 1.73, 95% CI = 1.33-2.26) and mild cognitive impairment (HR = 1.95, 95% CI = 1.42-2.67) increased all-cause mortality risk, associations that were also detected for noncardiovascular mortality. When individuals were free of cognitive impairment, a dose-response relationship with ε4 alleles was found for all-cause mortality (HR = 1.40, 95% CI = 0.94-2.07 for 1 ε4; HR = 2.61, 95% CI = 1.12-6.07 for 2 ε4). After onset of Alzheimer's disease (AD), carrying only one ε4 allele resulted in an approximately 77% greater all-cause mortality risk than in noncarriers. ApoE ε4 carrier status increased all-cause mortality risk in men and interacted with time-dependent AD to increase the risk of this outcome (relative excess risk due to interaction = 2.15, 95% CI = 1.22-3.07). CONCLUSION: ApoE ε4 carrier status was found to increase all-cause and cardiovascular mortality risks and interacted with sex and time-dependent AD status to affect all-cause mortality.
OBJECTIVES: To confirm associations of apolipoprotein E (ApoE) ε4 carrier status, sex, and time-dependent cognitive status with mortality risk and to investigate these joint effects of these associations in a cohort of community-dwelling U.S. adults. DESIGN: Prospective cohort study. SETTING: The Baltimore Longitudinal Study of Aging (BLSA). PARTICIPANTS: Of 3,047 BLSA participants aged 17 to 98 at first visit (60.1% male), 1,704 with complete ApoE genotype data were included, of whom 1,461 aged 50 and older with one or more visits were eligible. MEASUREMENTS: Time to death from all, cardiovascular, and noncardiovascular causes. RESULTS: Probability of survival was lower for ApoE ε4 carriers, particularly those who were older. A Cox proportional hazards model for all-cause mortality yielded a hazard ratio (HR) for ApoE ε4 carrier versus noncarriers of 1.31 (95% confidence interval (CI) = 1.02-1.68). This association was also found for cardiovascular mortality. Time-dependent all-cause dementia (HR = 1.73, 95% CI = 1.33-2.26) and mild cognitive impairment (HR = 1.95, 95% CI = 1.42-2.67) increased all-cause mortality risk, associations that were also detected for noncardiovascular mortality. When individuals were free of cognitive impairment, a dose-response relationship with ε4 alleles was found for all-cause mortality (HR = 1.40, 95% CI = 0.94-2.07 for 1 ε4; HR = 2.61, 95% CI = 1.12-6.07 for 2 ε4). After onset of Alzheimer's disease (AD), carrying only one ε4 allele resulted in an approximately 77% greater all-cause mortality risk than in noncarriers. ApoE ε4 carrier status increased all-cause mortality risk in men and interacted with time-dependent AD to increase the risk of this outcome (relative excess risk due to interaction = 2.15, 95% CI = 1.22-3.07). CONCLUSION:ApoE ε4 carrier status was found to increase all-cause and cardiovascular mortality risks and interacted with sex and time-dependent AD status to affect all-cause mortality.
Authors: May A Beydoun; Adel Boueiz; Marwan S Abougergi; Melissa H Kitner-Triolo; Hind A Beydoun; Susan M Resnick; Richard O'Brien; Alan B Zonderman Journal: Neurobiol Aging Date: 2010-07-08 Impact factor: 4.673
Authors: Jessica R Marden; Elizabeth R Mayeda; Stefan Walter; Alexandre Vivot; Eric J Tchetgen Tchetgen; Ichiro Kawachi; M Maria Glymour Journal: Alzheimer Dis Assoc Disord Date: 2016 Jul-Sep Impact factor: 2.703
Authors: James T Becker; Jeremy J Martinson; Sudhir Penugonda; Lawrence Kingsley; Samantha Molsberry; Sandra Reynolds; Aaron Aronow; Karl Goodkin; Andrew Levine; Eileen Martin; Eric N Miller; Cynthia A Munro; Ann Ragin; Ned Sacktor Journal: J Neurovirol Date: 2014-11-12 Impact factor: 2.643
Authors: Rebecca A Nebel; Neelum T Aggarwal; Lisa L Barnes; Aimee Gallagher; Jill M Goldstein; Kejal Kantarci; Monica P Mallampalli; Elizabeth C Mormino; Laura Scott; Wai Haung Yu; Pauline M Maki; Michelle M Mielke Journal: Alzheimers Dement Date: 2018-06-12 Impact factor: 21.566
Authors: Kumar B Rajan; Lisa L Barnes; Robert S Wilson; Elizabeth A McAninch; Jennifer Weuve; Dominique Sighoko; Denis A Evans Journal: J Am Geriatr Soc Date: 2017-09-12 Impact factor: 5.562